ISLAMABAD: Compared with hospitalized patients in China, a new study finds higher rates of abnormal liver tests among patients receiving treatment in hospitals in the United States.
Researchers analyzed liver tests from 1,827 patients with COVID-19. All were admitted to Yale-New Haven Health hospitals between March 14 and April 23, 2020.
These tests measure levels of enzymes that the liver releases into the bloodstream when it sustains damage.
An analysis of data from China suggests that around 15% of hospitalized COVID-19 patients had abnormal liver test results. However, 42–67% of the patients in the Yale study had abnormal tests upon admission to the hospital.
The researchers are unsure why the livers of COVID-19 patients in the U.S. are more likely to have sustained damage, but underlying health differences between Chinese and U.S. populations may be responsible.
The National Institutes of Health (NIH) estimate that 30–40% of adults in the U.S. have NAFLD. In addition, millions of people have chronic liver infections due to hepatitis B andhepatitis C.
0 Comments